DoJ says Aetna (CVS) agrees to pay USD 117.7mln to settle False Claims Act
Context
The settlement of USD 117.7 million under the False Claims Act by Aetna (part of CVS) signals regulatory scrutiny and potential risks for companies in the healthcare space. This payment may affect CVS's financials and investor sentiment, especially amidst ongoing discussions about healthcare regulations and compliance. Keep an eye on how this influences sector valuations and broader market perceptions regarding risk in the healthcare sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#AETNA INC#CVS CAREMARK CORP#CVS.US#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#METALS & MINING#S&P 500 INDEX#CVS HEALTH CORP#CVS#DXY#US EQUITIES